Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
[Cognitive impairment in demyelinating disease].
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.
Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Elevated Expression of the Cerebrospinal Fluid Disease Markers Chromogranin A and Clusterin in Astrocytes of Multiple Sclerosis White Matter Lesions.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Ginseng in the Treatment of Fatigue in Multiple Sclerosis: A Randomized Placebo-Controlled Double-Blind Pilot Study.
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Successful desensitization to natalizumab in a skin test--positive patient: a case report.
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Phenytoin protects central axons in experimental autoimmune encephalomyelitis.
Client-centred therapy in multiple sclerosis: More intensive diagnostic evaluation and less intensive treatment.
Epidermal pigmentation in the human lineage is an adaptation to ultraviolet radiation.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Symptom overlap in anxiety and multiple sclerosis.
Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis.]

Pages